Bioptimus

What is Bioptimus?

Bioptimus is a French AI company that develops foundation models for biology, combining histology, spatial transcriptomics and genomics to predict biological outcomes for drug development and diagnostics.

Key capabilities of Bioptimus

• H-Optimus-1: Pathology foundation model ranked first in independent PathBench benchmarks.
• M-Optimus: Multimodal model across pathology, spatial transcriptomics and genomics.
• STELA: Data engine producing clinically linked, deeply profiled patient data.
• Target discovery: Finds drug targets and biomarkers from histology slides.
• Treatment response: Predicts response and identifies spatial biomarkers.

How Bioptimus works

Researchers apply the foundation models to histology slides and related omics data to extract features and predict outcomes. H-Optimus-1 is available with public documentation, while access to M-Optimus requires contacting the company. STELA supplies clinically linked patient data through a collaborative partner network.

Who uses Bioptimus?

Pharmaceutical companies, biotech teams and research institutions. The vendor reports that 16 of the top 20 pharma companies and 1,000+ institutions use its models, with 1.18M+ downloads and 100+ peer-reviewed papers.

Bioptimus pricing

No prices are published. Contact the company for M-Optimus access and STELA partnerships.

Bioptimus alternatives

Related healthcare AI vendors include Aidoc and Viz.ai for imaging, Corti for clinical conversation AI, and Hippocratic AI. Bioptimus is a research foundation model provider rather than a clinical workflow tool.